Introduction
Malignant gliomas are the most common neoplasms in the central nervous system. When treated with conventional treatments including surgery, ␥-irradiation, and chemotherapy, the average life expectancy after diagnosis is usually less than 1 year. 1, 2 As with many other cancers, multistep accumulation of genetic aberrations is closely associated with malignant progression of astrocytic tumor. 3 Mutation or inactivation of the tumor-suppressor p53 or p16 gene was detected in most of the malignant glioma cell lines and primary brain tumors, but not in normal brain tissues. [4] [5] [6] [7] Based on these findings, therapies aiming at the restoration of wild-type p53 or p16 function may be of benefit. Actually, recent investigations have demonstrated the antitumor effect of p53 or p16 gene transfer against malignant glioma cells. [8] [9] [10] [11] [12] The introduction of p53 or p16 gene caused marked growth sup-and in vivo. Five malignant glioma cell lines expressing the mutant p53 gene (A172, GB-1, T98G, U251-MG and U373-MG) were more sensitive to the combination of 2-5A-antihTR and Ad5CMV-p53 than to other combinations. The additive effect of the combination therapy was due to induction of caspase-dependent apoptosis and cell growth arrest. Furthermore, the 2-5A-anti-hTR treatment when combined with Ad5CMV-p53 showed greater efficacy against subcutaneous U251-MG tumors in nude mice. In contrast, U87-MG cells expressing the wild-type p53 gene were insensitive to Ad5CMV-p53, although the treatment with 2-5A-anti-hTR was significantly effective. These results indicate that combining 2-5A-anti-hTR with Ad5CMV-p53 has the most therapeutic potential for malignant gliomas with mutant p53. For tumors exhibiting wild-type p53, it may be useful to treat with 2-5A-anti-hTR. Gene Therapy (2000) 7, 2071-2079. pression in malignant glioma cells without p53 or p16 function, but showed little effect on those cells with wildtype alleles of p53 or p16. 9, 10, 13, 14 Because most malignant gliomas are composed of heterogeneous cellular subpopulations with regard to the tumor-suppressor gene, 14 cancer gene therapy using p53 or p16 gene may be of limited clinical effectiveness.
Recently, the activity of telomerase has been proven to be essential for creation of human tumor cells. 15 Without the activation of telomerase, oncogene alone is not sufficient to render human cells malignant phenotypes. Telomerase activity, which is generally undetectable in normal somatic cells, is expressed in approximately 90% of tumors. [16] [17] [18] [19] Among malignant gliomas, telomerase was detected in 10 to 45% of anaplastic astrocytomas and in 75 to 89% of glioblastoma multiforme. 20, 21 In contrast, no normal brain tissues expressed the activity. These facts strongly support the idea that telomerase inhibition may represent a novel targeting approach for the treatment of malignant gliomas. Recently, it has been demonstrated that targeting the RNA template of telomerase (hTR) with antisense RNA [22] [23] [24] [25] or inhibiting the function of a catalytic protein subunit of telomerase (hTERT) with a dominant-negative mutant [26] [27] [28] showed a significant antitumor effect. We have recently synthesized a 19-mer antisense oligonucleotide against hTR linked 2-5A (5′-phosphorylated 2′-5′-linked oligoadenylate) (2-5A-anti-hTR) and demonstrated its cytotoxic effect on malignant glioma cells 29, 30 or prostate cancer cells. 31 The effect of 2-5A-antihTR was mainly due to induction of apoptosis. Based upon what is described above, we hypothesized that the treatment with 2-5A-anti-hTR would augment the efficacy of tumor-suppressor gene transfer to malignant glioma cells, by targeting telomerase, an essential molecule, still a separate element to the tumorsuppressor, of malignant tumors. In the present study, we investigated the efficacy of combining 2-5A-anti-hTR with recombinant adenoviruses bearing p53, its associated p21
, or p16 CDKN2 (Ad5CMV-p53, Ad5CMV-p21, or Ad5CMV-p16) against malignant glioma cells in vitro and in vivo. We demonstrate here that by induction of caspase-dependent apoptosis and cell growth arrest, the treatment with 2-5A-anti-hTR has greater efficacy when combined with Ad5CMV-p53 for malignant gliomas carrying the mutant p53 gene. Furthermore, 2-5A-anti-hTR can target malignant glioma cells with wildtype p53 which resist the p53 gene transfer.
Results
Telomerase activity in human malignant glioma cell lines To investigate telomerase activity in various malignant glioma cell lines, we performed the TRAP assay. As shown in Figure 1 , telomerase activity was detected in all cell lines we tested. The results indicated that all of them have potential for being targeted by the 2-5A-anti-hTR treatment.
In vitro antitumor effect of combining 2-5A-anti-hTR with Ad5CMV-p16, Ad5CMV-p21 or Ad5CMV-p53 By using Ad5CMV-␤-gal, we first ensured that the adenoviral infectivity to human malignant glioma cell lines we used in this study was Ͼ90% at an MOI of 60 for U87-MG, A172, GB-1, U251-MG and U373-MG cells, and at an MOI of 180 for T98G cells, respectively (data not shown). Next, we treated the six cell lines of maligant gliomas with 2-5A-anti-hTR in combination with Ad5CMV-p16, Ad5CMV-p21 or Ad5CMV-p53, respectively. As a control of adenoviral transfer, Ad5CMV-PA was used. As shown in Figure 2 , the antitumor effect of 2-5A-anti-hTR treatment was remarkable in all six cell lines, as expected from the results we previously reported. 29, 30 The viability of tumor cells was reduced between 20 and 70% after 4 days treatment with 2-5A-anti-hTR in the presence of lipofectamine. The cytotoxic effect of lipofectamine alone or control oligonucleotides with six mismatched nucleotides 29 mixed with lipofectamine was minimal (data not shown). Among the adenoviral treatment, the p53 transfer showed higher cytotoxicity than p16 or p21 treatment. In mutant p53-expressing A172, GB-1, T98G, U251-MG and U373-MG cells, Ad5CMV-p53 reduced the viability of tumor cells between 5 and 30%. In contrast, U87-MG cells exhibiting wild-type p53 were insensitive to the p53 infection, that corresponds with the previous reports. 9, 13, 14 Ad5CMV-p16 or Ad5CMV-p21 induced a moderate degree of antitumor effect against all malignant glioma cell lines. As a next step, we combined 2-5A-anti-hTR therapy with the adenoviral transfer of p16, p21, or p53, respectively. As shown in Figure 2 , the combination of 2-5A-anti-hTR and Ad5CMV-p53 had greater efficacy against all p53-mutant glioma cells than each treatment alone (P Ͻ 0.0001 to P Ͻ 0.01). The mean value of the fractional product parameter under this treatment condition was 1.05 for p53-mutant tumor cells, which is not statistically significant when compared to 1 (P Ͻ 0.0051). This indicated that the combination therapy with 2-5A-anti-hTR and Ad5CMV-p53 showed an additive, but not a synergistic or antagonistic effect. There was no enhancement of cytotoxicity by the combination in U87-MG cells, although the cells were significantly sensitive to the 2-5A-anti-hTR treatment when compared with the control treatment (Ad5CMV-PA and lipofectamine) (P Ͻ 0.01). Furthermore, 2-5A-anti-hTR showed higher cytotoxicity when combined with Ad5CMV-p53 than with Ad5CMV-p16 or Ad5CMV-p21 (P Ͻ 0.0005 to P Ͻ 0.05, respectively). In U87-MG cells, there was no significant difference in the antitumor effect between 2-5A-anti-hTR alone and its combination with the adenoviral transfer of p16, p21, or p53, respectively. These results indicated that combining 2-5A-antihTR with Ad5CMV-p53 showed an additive effect against p53-mutant tumor cells. For U87-MG cells expressing wild-type p53, there was no combination effect with p16, p21, or p53 when compared with 2-5A-anti-hTR treatment alone, although 2-5A-anti-hTR was significantly effective.
Induction of apoptosis with 2-5A-anti-hTR and Ad5CMV-p53 From the results of cell viability assays, the most efficient combination therapy is the treatment with 2-5A-anti-hTR 
) from days 2 to 5 (every 24 h). On day 6, the cell viability was determined using a trypan blue dye exclusion assay. Survival fractions were calculated from the mean cell viability of treated cells divided by that of cells with control treatment (Ad5CMV-PA and lipofectamine). U87-MG, A172, GB-1, U251-MG, and U373-MG cells were infected at 60 MOI, while 180 MOI was used for T98G cells. Results shown are the means ± s.d. of four independent experiments. (a) U87-MG, (b) A172, (c) GB-1, (d) T98G, (e) U251-MG, and (f) U373-MG.
and Ad5CMV-p53. Previously, we demonstrated that treatment with 2-5A-anti-hTR induced apoptosis in malignant glioma cells. 29 Malignant glioma cells, in addition, underwent apoptosis following the introduction of wild-type p53 gene. 8, 9 Therefore, we speculated that the combination effect might be mainly due to induction of apoptosis. We collected the attached tumor cells that were still alive and investigated whether the treatment with 2-5A-anti-hTR, Ad5CMV-p53, and their combination induced apoptosis in malignant glioma cells by Gene Therapy flow cytometric analysis using APO-BRDU kit. Obviously, treatment with 2-5A-anti-hTR or Ad5CMV-p53 induced apoptosis in 70 or 46% of attached U251-MG ( Figure 3A ) or in 30 or 24% of attached U373-MG cells ( Figure 3B ), respectively. Furthermore, we collected the attached tumor cells and investigated the effect of 2-5A-anti-hTR and Ad5CMV-p53 on cell cycle. As shown in Table 1 , Ad5CMV-p53 increased the percentage of cells in G1 phase and decreased the percentage of cells in S phase. On the other hand, there was no remarkable change in cell cycle after the 2-5A-anti-hTR treatment. As far as the attached cells were observed, the results indicated the possibility that the introduction of wild-type p53 gene might inhibit cell viability due to apoptosis induction and growth arrest, while the anti-tumor effect of 2-5A-anti-hTR might be maily due to apoptosis. To ascertain this, it may be necessary to collect both attached and detached cells, and to compare the G1 population with the subG1 population of treated cells by cell cycle analysis, although we gated dead cells out in this study.
Figure 3 Flow cytometric analysis of apoptotic cells after the treatment with 2-5A-anti-hTR and Ad5CMV-p53. After the treatment, U251-MG (A) or U373-MG (B) cells were fixed, labeled with Br-dUTP, stained with FITC-anti-BrDU antibody, and then analyzed by FACScan. The dots above the horizontal threshold line indicate the apoptotic cells. (a)
As expected, the extent of apoptosis was significantly enhanced by the combination of 2-5A-anti-hTR and Ad5CMV-p53 when compared with each treatment alone. The percentage of apoptotic cells treated with the combination was 96% in U251-MG or 65% in U373-MG cells, respectively ( Figure 3A and B). These results indicated that the effect of combination therapy was due to induction of apoptosis and growth arrest.
Involvement of caspases in the cytotoxic effect of combining 2-5A-anti-hTR with Ad5CMV-p53 Because caspases are the mainstay of apoptosis, they may play an important role in the cytotoxic effect of combination therapy. To investigate if the combination treatment with 2-5A-anti-hTR and Ad5CMV-p53 induced apoptosis in a caspase-dependent manner, we performed caspase inhibition assays using U251-MG cells. As shown in Figure 4 , the cell death of U251-MG by 2-5A-anti-hTR was almost completely rescued by the pretreatment with caspase-1 or caspase-3 inhibitor (P Ͻ 0.005 or P Ͻ 0.0001, respectively). On the other hand, the cell death following the adenoviral transfer of wild-type p53 was significantly suppressed by addition of caspase-3 inhibitor (P Ͻ 0.001), but not of caspase-1 inhibitor. Furthermore, caspase-1 or caspase-3 inhibitor significantly inhibited the cytotoxic effect of the combination therapy (P Ͻ 0.001 or P Ͻ 0.0001, respectively). Additionally, we demonstrated the involvement of caspase family in U373-MG cells treated with 2-5A-anti-hTR (data not shown). These results indicated that not only treatment with either 2-5A-anti-hTR or Ad5CMV-p53, but also their combination therapy induced caspase-dependent apoptosis in malignant glioma cells.
In vivo antitumor effect of combining 2-5A-anti-hTR with Ad5CMV-p53 Furthermore, we investigated whether the combination effect was also detected in in vivo animal models. As shown in Figure 5A , 2-5A-anti-hTR or Ad5CMV-p53 significantly suppressed the growth of U251-MG subcutane- ous tumors when compared with control treatment (P Ͻ 0.01 or P Ͻ 0.005, respectively). As speculated from in vitro experiments, the combining 2-5A-anti-hTR with Ad5CMV-p53 significantly inhibited the growth of U251-MG subcutaneous tumors more than each treatment alone (P Ͻ 0.05 or P Ͻ 0.005, respectively) ( Figure 5A ). The mean tumor volume after 7-day treatment with 2-5A-anti-hTR alone, Ad5CMV-p53 alone, or their combination was decreased to 68.0 ± 18.6%, 64.4 ± 8.9% or 33.2 ± 8.6% of the initial tumor size, respectively. In contrast, the mean tumor volume with control treatment (Ad5CMV-PA and lipofectamine) reached 190.9 ± 54.9% of the initial tumor volume. As shown in Figure 5B -b or 5B-c, some apoptotic cells were detected in tumor specimens treated with 2-5A-anti-hTR or Ad5CMV-p53, respectively. When compared with each treatment alone, the number of TUNEL-positive cells was relatively increased by the combination therapy ( Figure 5B-d) . In contrast, apoptotic cells were almost undetectable in tumors of control treatment ( Figure 5B-a) . These results indicated that combin- ing 2-5A-anti-hTR with Ad5CMV-p53 was more effective for malignant gliomas in vivo than each treatment alone and its antitumor effect was mainly due to induction of apoptosis.
Discussion
Adenovirus-mediated delivery of the p53 gene into p53 mutant malignant glioma cells was very effective, and its antitumor effect was greater than the 2-5A-anti-hTR treatment. More importantly, malignant glioma cells containing wild-type p53 gene were sensitive to 2-5A-anti-hTR, but insensitive to the p53 adenoviral transfer. Because most malignant gliomas are composed of p53 mutant and wild-type population, 14 p53 gene therapy alone may not be a clinically effective treatment. Therefore, the 2-5A-anti-hTR treatment combined with Ad5CMV-p53 may represent a therapeutically promising strategy for malignant gliomas.
Recent investigations indicate that the telomerase expression detected in 80-95% of human cancers [16] [17] [18] [19] 32 is essential for the continued growth of malignant cells. 15, 26 Therefore, it is expected that inhibition of telomerase Gene Therapy function may alter the growth properties of tumor cells and subsequently suppress the tumor growth. Since the RNA component of human telomerase (hTR) was first of all reported, 22 several strategies that target hTR with antisense RNA, [22] [23] [24] hammer head ribozyme 33 or peptide nucleic acids 34 were investigated. They reduced telomerase activity and tumor growth to some extent. Recently, two additional components of the human telomerase were identified: the telomerase-associated protein (TEP1) 35, 36 and the telomerase catalytic subunit or telomerase reverse transcriptase (hTERT). 37, 38 Although hTR and hTERT are essential for telomerase activity, the expression of hTERT is closely associated with telomerase activity. 39, 40 Therefore, to inhibit telomerase activity significantly, the hTERT may be more attractive as a target than the hTR. More recently, it has been demonstrated that the complete inhibition of telomerase using a dominant-negative mutant of hTERT resulted in reduction in telomere length and apoptotic death of tumor cells. [26] [27] [28] Inhibition of hTERT function is expected to be particularly effective for tumors with short telomere because its antitumor effect was telomere lengthdependent.
The target of 2-5A-anti-hTR used in the present study is the hTR as previously described.
29-31 2-5A-anti-hTR is linked to 2-5A to enhance the effect of antisense oligonucleotides. 2-5A is known as one pathway of interferon action. 41 2-5A activates RNase L that is ubiquitous in mammalian cells, and results in single-stranded RNA cleavage after UN sequences. 42 Antisense against a certain target linked to 2-5A causes the degradation of the targeted RNA in a highly specific manner, and enhances the potency of antisense at least 20-fold. [43] [44] [45] In the previous study, 2-5A-anti-hTR degraded hTR 5 h after the treatment and reduced the viability of malignant glioma cells to 20-30% 2 weeks later through induction of apoptosis. 29 The antitumor effect of 2-5A-anti-hTR was significantly enhanced by the use of a cationic liposome, lipofectamine, due to efficient uptake, and apoptotic cell death was detected in the vast majority of tumor cells within 4 days after treatment as described in the present study. What are the molecular mechanisms underlying the antitumor effect of 2-5A-anti-hTR? As described previously, it took approximately 1 month to induce apoptosis in 50% of U251-MG cells by telomere shortening following telomerase inhibition. 23 Until the cell crisis of U251-MG cells, the expression of caspase was not changed. On the other hand, treatment with 2-5A-antihTR for 4 days activated function of caspases and induced apoptosis in 70% of U251-MG cells. A similar caspase-dependent apoptosis by 2-5A-anti-hTR was observed in prostate cancer cells. 31 Based on this evidence, one possible explanation is that the antitumor effect of 2-5A-anti-hTR may be due to active induction of caspase-dependent apoptosis which is independent of telomere length. To treat tumors having long telomere, 2-5A-anti-hTR that degrades hTR and induces a caspasedependent apoptosis irrespective of telomere length, may be promising when compared with the treatment with inhibition of hTERT function.
It was previously demonstrated that there was no association between alterations in p53 or p16 and telomerase activity in immortalized human cells. 46 Additionally, telomerase activity was unaffected by overexpression of p53 in immortalized endothelial cells. 47 Conversely, it was reported that induced expression of wild-type p53 resulted in the down-regulation of telomerase activity in not only immortalized fibroblasts, 48 but also cancer cell lines. 49, 50 Furthermore, it has recently been demonstrated that severe telomere shortening in telomerase-deficient mice activated p53, leading to growth arrest and/or apoptosis. 51 Therefore, the relationship between dysfunction of the tumor suppressor genes and telomerase activity remains controversial. On the other hand, caspase family is involved in p53-dependent apoptosis, 52, 53 supporting the results in the present study that caspases are activated with p53 adenoviral transfer. Interestingly, the treatment with 2-5A-anti-hTR alone or its combination with Ad5CMV-p53 activated caspases-1 and -3, while caspase-3 was mainly involved in the p53 treatment. Therefore, the additive effect of combination therapy might be due to the activation of multiple components of caspase cascade.
In summary, combining 2-5A-anti-hTR with the adenoviral transfer of p53 gene has significantly greater antitumor effect for malignant gliomas without p53 function than each treatment alone. When tumors expressing wild-type p53 are treated, treatment with 2-5A-anti-hTR alone may be promising. This is the first report demonstrating the feasibility of combination therapy with degradation of telomerase RNA and restoration of p53 gene against malignant gliomas. Because telomerase activity or p53 dysfunction is commonly detected in a wide range of tumors, this approach may not only prove meaningful for the treatment of patients with malignant glioma, but for a wide spectrum of other malignancies.
Materials and methods

Tumor cells
Human malignant glioma U87-MG, A172, T98G, U373-MG cells were purchased from ATCC (American Tissue Culture Collection, Rockville, MD, USA). Human malignant glioma GB-1 and U251-MG cells were kindly gifted by Dr Tatsuo Morimura (National Utano Hospital, Kyoto, Japan), and Dr Akiko Nishiyama (University of Connecticut, Storrs, CT, USA), respectively. As for p53 status, U87-MG cells were the only cell lines expressing the wild-type p53 gene.
54 A172, GB-1, T98G, U373-MG and U251-MG cells had mutant p53. 54, 55 Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GIBCO BRL), 4 mm glutamine, 100 U/ml penicillin and 100 g/ml streptomycin.
Synthesis of 2-5A-anti-hTR
The selection of the antisense against hTR was described previously. 29 Briefly, we designed the 2-5A antisense oligonucleotide (2-5A-anti-hTR) to the region between residues 76 and 94, because this part was predicted to be the most open by the MFOLD computer program (SEQL program; Laboratory of Mathematical Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA). The sequence of the antisense is 5′-GCG CGG GGA GCA AAA GCA C-3′. The specificity of 2-5A-antihTR was previously ensured compared with control oligonucleotides. 29 This chimeric oligonucleotide synthesized on solid supports and purified as described previously, 29 was a gift from Dr Robert H Silverman and Dr John K Cowell (Cleveland Clinic, OH, USA) or were synthesized at Hybridon (Milford, MA, USA).
Recombinant adenovirus
The recombinant Ad5CMV-p53, Ad5CMV-p21 and Ad5CMV-p16 containing CMV promoter, p53, p21 WAF1/CIP1 or p16 CDKN2 complement cDNAs and SV40 polyadenylation signal were constructed by inserting the expression cassette into the E1-deleted region of modified Ad5 genome. 56, 57 The recombinant control adenovirus (Ad5CMV-PA) was constructed in a similar manner. Ad5CMV-PA is an empty vector which contains no cDNA between CMV promoter and PA (poly adenylation signal). Viral stocks were propagated in 293 cells and purified through C s Cl 2 banding as described previously. 56, 57 Adenoviral infectivity to human cancer cell lines in vitro was routinely determined by the use of a recombinant adenovirus bearing a ␤-galactosidase, Ad5CMV-␤-gal. 56, 57 Telomerase activity (TRAP) assay The TRAP assay was performed with TRAPEZE Telomerase Detection Kit (Oncor, Gaithersburg, MD, USA) according to the manufacturer's instructions with some minor modifications. 17, 23, 29 Cells were washed once in PBS, and homogenized in 50 l of ice-cold lysis buffer. After 30 min of incubation on ice, the lysates were centrifuged at 10 000 g for 15 min at 4°C, and the supernatant was rapidly frozen and stored at −80°C. The concentration of protein was measured using the BioRad Protein Assay (Richmond, CA, USA). Each extract (200 ng protein) was assayed in a 50 l reaction mixture containing; 5 l of 10 × TRAP Reaction Buffer, 50 m deoxynucleotide triphosphates, 0.2 to 0.4 l of ␣- An internal telomerase activity standard (ITAS, 36 bp) was included in the Primer Mix. After a 30-min incubation at room temperature for telomerase extension, the reaction mixture was then subjected to PCR amplification in a thermal cycler for 30 cycles at 94°C for 30 s, 50°C for 30 s, and 72°C for 1.5 min. The PCR product was electrophoresed in 0.5 × Tris-borate EDTA on a 6% polyacrylamide gel. The gel was then dried and autoradiography was performed. Radioactivity was also quantitated with a Molecular Dynamics PhosphorImager (Sunnyvale, CA, USA).
Cell viability assay
The cytotoxic effect of the recombinant adenovirus with or without 2-5A-anti-hTR on tumor cells was determined by using a trypan blue dye exclusion assay as described previously. 29 The cells were seeded at 3-5 × 10 3 cells per well (0.1 ml) in 96-well flat-bottomed plates and incubated overnight at 37°C. Then, the cells were infected with Ad5CMV-PA (as a control), Ad5CMV-p16, Ad5CMV-p21, or Ad5CMV-p53 (day 1), respectively, as described previously. 56, 57 To achieve the infectivity of Ͼ90%, U87-MG, A172, GB-1, U251-MG and U373-MG cells were tested at a multiplicity of infection (MOI) of 60 p.f.u. per cell. On the other hand, T98G cells were infected with 180 MOI. After overnight incubation, the virus-containing medium was removed. Then, 2-5A-antihTR (5.0 m) with a cationic lipid (lipofectamine, GIBCO BRL, 0.4 l) in 10 l sterile distilled water was added to the wells. After the incubation for 2 min, 90 l of fresh medium was added. The final concentration of 2-5A-antihTR was 0.5 m. As a control, lipofectamine (0.4 l) alone in 10 l sterile distilled water was used. This 2-5A-antihTR treatment was performed every 24 h for 4 days (days 2-5). On day 6, the number of viable cells in each well was counted. Survival fractions were calculated from the mean cell viability of treated cells divided by that of cells with control treatment (Ad5CMV-PA and lipofectamine). It is because the viability of cells treated with Ad5CMV-PA and lipofectamine was 10-15% less than that of uninfected (mock) cells.
Flow cytometric analysis of apoptosis Apoptosis of treated tumor cells was detected using the APO-BRDU kit (Pharmingen, San Diego, CA, USA), according to the manufacturer's instructions. Briefly, the 3′-hydroxyl ends of the DNA in apoptotic cells were labeled with bromolated deoxyuridine triphosphate nucleotides (Br-dUTP) by terminal deoxynucleotidyl transferase, and the incorporated BrdU was stained with a Gene Therapy fluorescein isothiocyanate (FITC)-labeled anti-BrdU monoclonal antibody. After DNA was stained with propidium iodide, the cells were analyzed by FACScan.
Cell cycle analysis
For cell cycle analysis, trypsinized cells were stained with propidium iodide by using the Cycletest kit (Becton Dickinson, Mountain View, CA, USA) and analyzed for DNA content by using the FACScan (Becton Dickinson) as previously described. 23 Dead cells were gated out by using pulse processing.
Caspase inhibition assay Functional involvement of caspases was examined with inhibition of the enzymes as previously described.
31
U251-MG cells were seeded at 3-5 × 10 3 cells per well (0.1 ml) in 96-well flat-bottomed plates and incubated overnight at 37°C. Every 24 h, the cells were preincubated for an hour with either ICE (caspase 1) inhibitor or CPP32 (caspase 3) inhibitor (Biomol Research Laboratories, Plymouth Meeting, PA, USA) solubilized in DMSO at a concentration of 100 m. Then, the cells were treated with Ad5CMV-PA or Ad5CMV-p53 at a MOI of 60 p.f.u. per cell on day 1, followed by treatment with 0.5 m of 2-5A-anti-hTR from days 2 to 5 (every 24 h), in the presence of one of the inhibitors (100 m). The cell viability and survival fractions were determined as described above.
In vivo treatment
For subcutaneous tumors, U251-MG cells (1.0 × 10 6 cells in 0.05 ml serum-free DMEM and 0.05 ml Matrigel (Collaborative Research, Bedford, MA, USA)) were inoculated subcutaneously into the right flank of 8-12-week-old male Balb/c nude mice (six mice for each treatment group), respectively. Tumor growth was monitored by using calipers every other day. Tumor volume (V) was calculated as (L × W 2 )/2, where L = length (mm) and W = width (mm) as described previously.
29-31 2-5A-antihTR treatment with or without Ad5CMV-PA or Ad5CMV-p53 was initiated when the tumors reached a mean tumor volume of 32-40 mm 3 . We chose to treat the animals after the establishment of the tumor to simulate the clinical situation. The percentage of increase in tumor volume was determined and compared with the tumor size before treatment. For recombinant adenoviral treatment, 6 × 10 7 p.f.u. of Ad5CMV-PA or Ad5CMV-p53 in 50 l serum-free DMEM was administered by direct injection into the tumor on days 1, 3 and 5, respectively. For anti-telomerase RNA treatment, 2-5A-anti-hTR (1 nmol/40 l sterile distilled water) with lipofectamine (0.3 l) or 40 l sterile distilled water with lipofectamine (0.3 l) as a control were administered by direct injection into the tumor every 24 h for 7 days, respectively. For histological analysis, mice were killed by cervical dislocation a day after the last treatment, and the tumors were removed and snap-frozen in liquid nitrogen. The specimens were embedded in OCT compound and cut 8.0 m in thickness. For TUNEL assays, the frozen sections were stained according to the manufacturer's instructions (Oncor) as described previously. 29 During all these experiments, which were approved by the CCF Research Programs Committee, the animals were housed and handled in accordance with the National Institutes of Health guidelines.
Statistical analysis
The data were expressed as means ± standard deviation (s.d.). The Bliss synergism was tested by calculating the fractional product parameter as described previously. 58 Cytotoxic fractions (c.f.) were calculated as 1 − survival fractions (s.f.). The fractional product value is defined as c.f. s t test (two-tailed) . The criterion for statistical significance was taken as P Ͻ 0.05.
